MX2018004595A - Terapia combinada para el tratamiento de neoplasias malignas. - Google Patents

Terapia combinada para el tratamiento de neoplasias malignas.

Info

Publication number
MX2018004595A
MX2018004595A MX2018004595A MX2018004595A MX2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A MX 2018004595 A MX2018004595 A MX 2018004595A
Authority
MX
Mexico
Prior art keywords
combination therapy
treating malignancies
treating
aml
malignancies
Prior art date
Application number
MX2018004595A
Other languages
English (en)
Inventor
V Agresta Samuel
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2018004595A publication Critical patent/MX2018004595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan métodos y composiciones para tratar la AML en pacientes portadores de una mutación de IDH2 usando una combinación de un inhibidor de una enzima IDH2 mutante y una terapia de inducción y consolidación para tratar la AML.
MX2018004595A 2015-10-15 2016-10-14 Terapia combinada para el tratamiento de neoplasias malignas. MX2018004595A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242256P 2015-10-15 2015-10-15
US201562255194P 2015-11-13 2015-11-13
PCT/US2016/057083 WO2017066599A1 (en) 2015-10-15 2016-10-14 Combination therapy for treating malignancies

Publications (1)

Publication Number Publication Date
MX2018004595A true MX2018004595A (es) 2019-07-04

Family

ID=57208385

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004595A MX2018004595A (es) 2015-10-15 2016-10-14 Terapia combinada para el tratamiento de neoplasias malignas.
MX2022006701A MX2022006701A (es) 2015-10-15 2018-04-13 Terapia combinada para el tratamiento de neoplasias malignas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006701A MX2022006701A (es) 2015-10-15 2018-04-13 Terapia combinada para el tratamiento de neoplasias malignas.

Country Status (15)

Country Link
US (2) US10905692B2 (es)
EP (2) EP4147692A1 (es)
JP (2) JP2018534288A (es)
KR (1) KR20180063125A (es)
CN (1) CN108366980A (es)
AU (1) AU2016340087C1 (es)
BR (1) BR112018007304A2 (es)
CA (1) CA3001599A1 (es)
CL (1) CL2018000927A1 (es)
EA (1) EA201890968A1 (es)
IL (1) IL258269A (es)
MX (2) MX2018004595A (es)
SG (1) SG10201912886XA (es)
WO (1) WO2017066599A1 (es)
ZA (1) ZA201802088B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
WO2017066611A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
IL265126B2 (en) 2016-09-07 2023-12-01 Celgene Corp Composition of tablets of 2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5- TRIAZIN–2–YL)AMINO]PROPAN–2–OL AND ITS SALTS
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
JP7305613B2 (ja) * 2017-07-09 2023-07-10 バイオサイト リミテッド 併用がん療法
US10980788B2 (en) * 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US20210403452A1 (en) 2018-11-02 2021-12-30 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
KR20220101148A (ko) 2019-11-14 2022-07-19 셀진 코포레이션 암의 치료를 위한 소아용 제제
CN111087408B (zh) * 2020-01-03 2021-04-02 浙江大学 一种大环结构的idh2突变体抑制剂及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
CA2793836C (en) * 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
KR101893112B1 (ko) 2012-01-06 2018-08-30 아지오스 파마슈티컬스 아이엔씨. 치료학적으로 활성인 화합물 및 이의 이용 방법
JP6471155B2 (ja) 2013-07-11 2019-02-13 アギオス ファーマシューティカルス，インコーポレーテッド 癌の治療のためのｉｄｈ２変異体阻害剤としてのｎ，６−ビス（アリール又はヘテロアリール）−１，３，５−トリアジン−２，４−ジアミン化合物
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
JP6742905B2 (ja) 2013-08-02 2020-08-19 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性のある化合物及びその使用方法
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
JP6816106B2 (ja) 2015-08-05 2021-01-20 アジオス ファーマシューティカルズ， インコーポレイテッド ６−ピリジル−１，３，５−トリアジン−２，４−ジオール及び６−ピリジル−１，３，５−トリアジン−２，４−ジアミンを調製する方法
WO2017066611A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
AU2016363011B2 (en) 2015-12-04 2022-07-14 Les Laboratoires Servier Methods of treatment of malignancies
EP3419593B1 (en) 2016-02-26 2022-03-23 Celgene Corporation Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia

Also Published As

Publication number Publication date
JP2018534288A (ja) 2018-11-22
JP2021130682A (ja) 2021-09-09
CN108366980A (zh) 2018-08-03
KR20180063125A (ko) 2018-06-11
EP4147692A1 (en) 2023-03-15
AU2016340087C1 (en) 2022-08-18
US10905692B2 (en) 2021-02-02
US20180311249A1 (en) 2018-11-01
AU2016340087B2 (en) 2022-05-12
AU2016340087A1 (en) 2018-04-12
US20210386749A1 (en) 2021-12-16
CL2018000927A1 (es) 2018-09-14
SG10201912886XA (en) 2020-02-27
ZA201802088B (en) 2021-07-28
MX2022006701A (es) 2022-07-12
CA3001599A1 (en) 2017-04-20
IL258269A (en) 2018-05-31
WO2017066599A1 (en) 2017-04-20
BR112018007304A2 (pt) 2018-10-23
EP3362057A1 (en) 2018-08-22
EA201890968A1 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
MX2022006701A (es) Terapia combinada para el tratamiento de neoplasias malignas.
MX2018004599A (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
ZA201803162B (en) Combination therapy for treating malignancies
MX2018004586A (es) Terapia de combinacion para tratar tumores malignos.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
MX2019007648A (es) Composiciones y metodos para la induccion de celulas t cd8+.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2015012054A (es) Inhibidores covalentes de kras g12c.
CL2015002807A1 (es) Terapia de combinación
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MX2017003797A (es) Macrociclos peptidomimeticos y usos de los mismos.
MX2018006152A (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico.
MY190411A (en) Improved uricase sequences and methods of treatment
MA40271A (fr) Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib
MX2021006408A (es) Terapia de combinacion de radioinmunoconjugados con inhibidores de da?os y reparaciones del adn.
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
MX2013007171A (es) Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
MX2019010981A (es) Terapias de combinacion para el tratamiento de cancer de mama.